Observational studyCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2025
Comparison of Fixed-Dose Clopidogrel/Asetylsalicylic Acid Combination and Standard Loading Strategy During Percutaneous Coronary Intervention in Chronic Coronary Syndrome.
Observational study in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparison of Fixed-Dose Clopidogrel/Asetylsalicylic Acid Combination and Standard Loading Strategy During Percutaneous Coronary Intervention in Chronic Coronary Syndrome.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDual antiplatelet therapy (DAPT), comprising acetylsalicylic acid and a P2Y12 receptor inhibitor such as clopidogrel, is the cornerstone of management in patients undergoing percutaneous coronary intervention (PCI). While conventional loading doses of acetylsalicylic acid and clopidogrel are well established, there is limited evidence supporting the use of fixed-dose combinations (FDCs) for loading therapy in patients with chronic coronary syndrome (CCS).
aimsThis study aims to evaluate the efficacy and safety of an FDC of clopidogrel and acetylsalicylic acid (75/75 mg, four tablets) compared to the standard loading regimen in patients with CCS undergoing elective PCI.
methodsIn this prospective observational study, patients were divided into two groups based on the antiplatelet loading strategy: conventional loading (acetylsalicylic acid 300 mg and clopidogrel 300-600 mg) and FDC group (four tablets of 75/75 mg). Baseline demographic, clinical, laboratory, and procedural characteristics were compared. The primary outcomes were 1-month rates of major adverse cardiovascular events (MACE), stent thrombosis, bleeding (BARC criteria), and mortality.
resultsA total of 410 patients were included (conventional: 326; FDC: 84). There were no statistically significant differences in baseline demographic or procedural characteristics between the groups. Laboratory findings and 1-month clinical outcomes, including MACE, bleeding, and mortality, were similar (p > 0.05 for all outcomes).
conclusionFixed-dose clopidogrel/acetylsalicylic acid combination may be a feasible and clinically comparable option in carefully selected CCS patients to standard loading in CCS patients undergoing elective PCI. Its use may simplify treatment regimens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.